Resumen
As increasing numbers of elderly people undergo cardiac surgery, neurologists are frequently called upon to assess patients with neurological complications from the procedure. Some complications mandate acute intervention, whereas others need longer term observation and management. A large amount of published literature exists about these complications and guidance on best practice is constantly changing. Similarly, despite technological advances in surgical intervention and modifications in surgical technique to make cardiac procedures safer, these advances often create new avenues for neurological injury. Accordingly, rapid and precise neurological assessment and therapeutic intervention rests on a solid understanding of the evidence base and procedural variables.
| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 490-502 |
| Número de páginas | 13 |
| Publicación | The Lancet Neurology |
| Volumen | 13 |
| N.º | 5 |
| DOI | |
| Estado | Published - may 2014 |
Nota bibliográfica
Funding Information:This work was funded by the Duke University Department of Anesthesiology and was supported in part by grants HL096978, HL108280, and HL109971 (to JPM) from the National Institutes of Health (Washington, DC, USA). We thank Kathy Gage (Department of Anesthesiology Duke University, NC, USA) for editorial assistance.
Funding Information:
DLM is a consultant for Cephalogics Corporation, LLC. CG receives research funding from Edge Therapeutics, AstraZeneca, Ornim, and Zoll Corporation. The other authors declare that they have no competing interests.
Financiación
This work was funded by the Duke University Department of Anesthesiology and was supported in part by grants HL096978, HL108280, and HL109971 (to JPM) from the National Institutes of Health (Washington, DC, USA). We thank Kathy Gage (Department of Anesthesiology Duke University, NC, USA) for editorial assistance. DLM is a consultant for Cephalogics Corporation, LLC. CG receives research funding from Edge Therapeutics, AstraZeneca, Ornim, and Zoll Corporation. The other authors declare that they have no competing interests.
| Financiadores | Número del financiador |
|---|---|
| Edge Therapeutics | |
| ZOLL Medical Corporation | |
| National Institutes of Health (NIH) | |
| National Heart, Lung, and Blood Institute (NHLBI) | R21HL108280 |
| AstraZeneca | |
| Duke-Kunshan University | HL096978, HL109971 |
ASJC Scopus subject areas
- Clinical Neurology
Huella
Profundice en los temas de investigación de 'Neurological complications of cardiac surgery'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver